Evaluation of neurovirulence and biodistribution of Venezuelan equine encephalitis replicon particles expressing herpes simplex virus type 2 glycoprotein D

Vaccine. 2007 Mar 8;25(12):2296-305. doi: 10.1016/j.vaccine.2006.11.063. Epub 2006 Dec 12.

Abstract

The safety of a propagation-defective Venezuelan equine encephalitis virus (VEEV) replicon particle vaccine was examined in mice. After intracranial inoculation we observed approximately 5% body weight loss, modest inflammatory changes in the brain, genome replication, and foreign gene expression. These changes were transient and significantly less severe than those caused by TC-83, a live-attenuated vaccinal strain of VEEV that has been safely used to immunize military personnel and laboratory workers. Replicon particles injected intramuscularly or intravenously were detected at limited sites 3 days post-administration, and were undetectable by day 22. There was no evidence of dissemination to spinal cord or brain after systemic administration. These results demonstrate that propagation-defective VEEV replicon particles are minimally neurovirulent and lack neuroinvasive potential.

MeSH terms

  • Animals
  • Body Weight
  • Brain / metabolism
  • Brain / virology
  • Encephalitis Virus, Venezuelan Equine / genetics
  • Encephalitis Virus, Venezuelan Equine / immunology*
  • Encephalomyelitis, Venezuelan Equine / immunology*
  • Encephalomyelitis, Venezuelan Equine / prevention & control
  • Injections, Intramuscular
  • Injections, Intravenous
  • Mice
  • RNA, Viral / genetics
  • RNA, Viral / metabolism
  • Replicon / genetics*
  • Reverse Transcriptase Polymerase Chain Reaction
  • Spinal Cord / metabolism
  • Spinal Cord / virology
  • Vaccines, Attenuated / administration & dosage
  • Vaccines, Attenuated / genetics
  • Vaccines, Attenuated / immunology
  • Viral Envelope Proteins / genetics*
  • Virus Replication / genetics

Substances

  • RNA, Viral
  • Vaccines, Attenuated
  • Viral Envelope Proteins
  • glycoprotein D-herpes simplex virus type 2